NovoCure Ltd
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About NovoCure Ltd
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.
/ 
Others were interested in
See all stocksFrequently asked questions
To buy NovoCure Ltd stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for NovoCure Ltd by name or ticker, choose the number of shares, and place your order.
The ticker symbol for NovoCure Ltd is NVCR:xnas. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
NovoCure Ltd has its primary listing on NASDAQ. You can trade NovoCure Ltd with a Saxo account, alongside thousands of other stocks worldwide.
Yes, NovoCure Ltd is available to trade on SaxoInvestor and SaxoTraderGO. You can buy shares directly and include NovoCure Ltd as part of a broader investment portfolio. Explore our SaxoInvestor platform.
Learn more about investing and trading at Saxo’s educational content hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures— so you can make more informed decisions when considering shares like NovoCure Ltd.